Alternatives to VI Therapeutics

A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.

A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.

Developing novel therapeutics for rare genetic diseases.

Biopharmaceutical startup developing novel therapies for rare genetic diseases.

Computational platform using LLMs trained on biological and chemical data for drug discovery.

AI-driven platform for protein-level disease mapping and drug discovery.

AI-powered blood test for early cancer detection and subtyping.

Personalized medicine startup focused on accurate cancer treatment through advanced diagnostics and functional drug sensitivity testing.

AI-powered epiproteomic analysis platform for mass spectrometry data.

AI-powered insights platform for life sciences and biotech workflows.

Compressing biology to develop the next generation of therapies.

Revolutionizing prenatal testing with non-invasive fetal DNA analysis from maternal blood.

Synthetic biology startup optimizing gene expression for food and biotech applications.

Cloud-based platform for reproducible computational research in life sciences.

Developing polymer-based nanoparticles for targeted gene therapy delivery.

Biopharmaceutical company developing human haploid stem cells for regenerative medicine and disease therapy.

OncoDecipher uses silent mutations in cancer genomes to predict cancer type and survival probability.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).